A practical reference on prohibited list: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-16 and is reviewed periodically as new material appears.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
=== EC 2.8.2: Sulfotransferases === EC 2.8.2.1: aryl sulfotransferase EC 2.8.2.2: alcohol sulfotransferase EC 2.8.2.3: amine sulfotransferase EC 2.8.2.4: estrone sulfotransferase EC 2.8.2.5: chondroitin 4-sulfotransferase EC 2.8.2.6: choline sulfotransferase EC 2.8.2.7: UDP-N-acetylgalactosamine-4-sulfate sulfotransferase EC 2.8.2.8: [heparan sulfate]-glucosamine N-sulfotransferase EC 2.8.2.9: tyrosine-ester sulfotransferase EC 2.8.2.10: Renilla-luciferin sulfotransferase EC 2.8.2.11: galactosylceramide sulfotransferase EC 2.8.2.12: deleted, identical to EC 2.8.2.8, [heparan sulfate]-glucosamine N-sulfotransferase EC 2.8.2.13: psychosine sulfotransferase EC 2.8.2.14: bile salt sulfotransferase EC 2.8.2.15: steroid sulfotransferase EC 2.8.2.16: thiol sulfotransferase EC 2.8.2.17: chondroitin 6-sulfotransferase EC 2.8.2.18: cortisol sulfotransferase EC 2.8.2.19: triglucosylalkylacylglycerol sulfotransferase EC 2.8.2.20: protein-tyrosine sulfotransferase EC 2.8.2.21: keratan sulfotransferase EC 2.8.2.22: aryl-sulfate sulfotransferase EC 2.8.2.23: [heparan sulfate]-glucosamine 3-sulfotransferase 1 EC 2.8.2.24: desulfoglucosinolate sulfotransferase EC 2.8.2.25: flavonol 3-sulfotransferase EC 2.8.2.26: quercetin-3-sulfate 3′-sulfotransferase EC 2.8.2.27: quercetin-3-sulfate 4′-sulfotransferase EC 2.8.2.28: quercetin-3,3′-bissulfate 7-sulfotransferase EC 2.8.2.29: [heparan sulfate]-glucosamine 3-sulfotransferase 2 EC 2.8.2.30: [heparan sulfate]-glucosamine 3-sulfotransferase 3 EC 2.8.2.31: petromyzonol sulfotransferase EC 2.8.2.32: scymnol sulfotransferase EC 2.8.2.33: N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase EC 2.8.2.34: glycochenodeoxycholate sulfotransferase EC 2.8.2.35: dermatan 4-sulfotransferase EC 2.8.2.36: desulfo-A47934 sulfotransferase EC 2.8.2.37: trehalose 2-sulfotransferase EC 2.8.2.38: aliphatic desulfoglucosinolate sulfotransferase EC 2.8.2.39: hydroxyjasmonate sulfotransferase EC 2.8.2.40: ω-hydroxy-β-dihydromenaquinone-9 sulfotransferase
Surfactant protein D, also known as SP-D, is a lung surfactant protein part of the collagenous family of lectins called collectin. In humans, SP-D is encoded by the SFTPD gene and is part of the innate immune system. Each SP-D subunit is composed of an N-terminal domain, a collagenous region, a nucleating neck region, and a C-terminal lectin domain. Three of these subunits assemble to form a homotrimer, which further assemble into a tetrameric complex.
High-power LEDs (HP-LEDs) or high-output LEDs (HO-LEDs) can be driven at currents from hundreds of mA to more than an ampere, compared with the tens of mA for other LEDs. Some can emit over a thousand lumens. LED power densities up to 300 W/cm2 have been achieved. Since overheating is destructive, the HP-LEDs must be mounted on a heat sink to allow for heat dissipation. If the heat from an HP-LED is not removed, the device fails in seconds. One HP-LED can often replace an incandescent bulb in a flashlight, or be set in an array to form a powerful LED lamp. Some HP-LEDs in this category are the Nichia 19 series, Lumileds Rebel Led, Osram Opto Semiconductors Golden Dragon, and Cree X-lamp. As of September 2009, some HP-LEDs manufactured by Cree exceed 105 lm/W. Examples for Haitz's law—which predicts an exponential rise in light output and efficacy of LEDs over time—are the CREE XP-G series LED, which achieved 105 lm/W in 2009 and the Nichia 19 series with a typical efficacy of 140 lm/W, released in 2010.
=== Birds === Close to ninety percent of known avian species are monogamous, compared to five percent of known mammalian species. The majority of monogamous avians form long-term pair bonds which typically result in seasonal mating: these species breed with a single partner, raise their young, and then pair up with a new mate to repeat the cycle during the next season. Some avians such as swans, bald eagles, California condors, and the Atlantic Puffin are not only monogamous, but also form lifelong pair bonds. When discussing the social life of the bank swallow, Lipton and Barash state:
Sources: en.wikipedia.org
== Genetic methods == The yeast two-hybrid and bacterial two-hybrid assays investigate interactions between artificial fusion proteins. They do not require isolation of proteins but rather use transformation to express proteins in yeast or bacteria, respectively. The cells are designed in a way that an interaction activates the transcription of a reporter gene or a reporter enzyme. These methods allow easy screening of interactions and libraries with high throughput (see two-hybrid screening).
Significance of research: All experiments are carried out at 60 °C. Changes in the equilibrium constant (K) are used to determine what type of lipid interactions are occurring within the modeled membrane as well as observe liquid-ordered versus liquid-disorder regions. The value of the equilibrium constant determine the following: 1) if monomers are mixed ideally (K = 4.0) 2) when the monomers are mixed homogenously also referred to as a homo-association (K < 4.0) and 3) if the monomers have interchanged heterogeneously which is referred to as an hetero-association (K > 4.0) A plot of (K) is then created versus the cholesterol mol%. Each plot has similar trends in which the value of the equilibrium constant increased as the mol% increased with and without the presence of ethanol indicating a linear regression. Initially all the model membranes were organized in a liquid order phase but as the addition of cholesterol increase a liquid-disorder phase was observed. The following was determined regarding the liquid-order and liquid-disordered transitions during the addition of cholesterol in the presence of ethanol in each model membrane: 1) 0–15 mol% cholesterol a liquid-disordered phase was present 2) from 15 to 30 mol% there was a co-existence of both phases and 3) above 27 mole% of cholesterol the model membrane completed converted back to the original liquid-order phase within a two-hour time frame. The linear regression maxed out at 30 mol% of cholesterol.
El Tony Montana was said to have overseen violent actions and logistics, and bought weapons and laundered money for the cartel. On 19 November 2024, El Mencho's son-in-law Cristian Fernando Gutierrez-Ochoa, a high ranking CJNG leader and romantic partner of El Mencho's daughter Laisha who notably faked his death and took up residency in California under an assumed identity, was arrested in Riverside, California. On 20 June 2025, Gutierrez-Ochoa, also known as "El Gaucho", pled guilty in the United States to one count of international money laundering conspiracy, with the charge resulting in him facing a maximum penalty of 20 years in prison. In his guilty plea, El Gaucho admitted to being vital to CJNG's money laundering operation, especially from at least 2023 up to his arrest in 2024, using sophisticated money laundering methods involving real estate transactions, shell companies, and international money transfers in order to launder CJNG's drug trafficking proceeds. On 18 December 2025, Gutierrez-Ochoa was sentenced to serve 140 months (more than 11 years) in a U.S. federal prison. On 28 February 2025, El Mencho's older brother Abraham, also known "Don Rodo", was recaptured by Mexican authorities. The arrest came a year after Don Rodo was briefly imprisoned for nine days after being arrested in April 2024.
Aside from petroleum and natural gas, alkanes occur significantly in nature only as methane, which is produced by some archaea by the process of methanogenesis. These organisms are found in the gut of termites and cows. The methane is produced from carbon dioxide or other organic compounds. Energy is released by the oxidation of hydrogen:
McKew said that "Putin and his minions have spent the past 15 years ranting about how the West (specifically NATO) wants a new Cold War". She suggested that "fighting a new Cold War would be in America's interest", adding "We won the last Cold War. We will win the next one too". The New Republic editor Jeet Heer criticised McKew's suggestion as "troubling" and for "wildly overstating the extent of Russian ambitions and power". Heer said that unlike the old Cold War, "Current U.S. troubles with Russia aren't the result of ideological differences ... and are intensely localized along Russia's borders, in countries like the Ukraine and Georgia". Jeremy Shapiro, a senior fellow in the Brookings Institution, wrote in his blog post at RealClearPolitics, referring to the US–Russia relations: "A drift into a new Cold War has seemed the inevitable result" of "Russian–Western confrontation" over Eastern European counties such as Ukraine, Moldova and Georgia. In August 2017, Russian Deputy Foreign Minister Sergei Ryabkov denied claims that the US and Russia were having another cold war, despite ongoing tensions between the two countries over Ukraine and Syria, and newer US sanctions against Russia. The University of East Anglia graduate student Oliver Steward, as well as the Casimir Pulaski Foundation senior fellow Stanisław Koziej, attributed the Russia's Zapad 2017 exercise in Belarus as part of the new Cold War between Russia and the West.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.